<DOC>
	<DOCNO>NCT02581748</DOCNO>
	<brief_summary>Assessment safety HLX02 different dos . Randomised , double-blind , parallel group Phase I study compare PK profile assess safety immunogenicity HLX02 Herceptin® ( U.S. German ) .</brief_summary>
	<brief_title>A Safety Pharmacokinetic Study Between HLX02 Herceptin® ( U.S. German ) Healthy Chinese Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Provide sing informed consent form ( ICF ) 2 . Healthy Chinese male subject ( healthy define clinically relevant abnormality identify detailed medical history , full physical examination include blood pressure pulse rate measurement , 12 lead ECG , clinical laboratory test ) 3 . Aged ≥18 ≤45 year 4 . Body mass index ( BMI ) ≥19 ≤28 kg/m2 5 . Weight ≥50 ≤80 kg 6 . Left ventricular ejection fraction ( LVEF ) fall within normal range measure echocardiogram ( ECHO ) within 14 day prior randomisation 7 . Subjects must agree female spouse/partners use reliable contraception ( 2 form birth control , one must barrier method ) nonchildbearing potential time administration investigational product ( IP ) completion study 8 . Do smoke smoke few 5 cigarette daily within three month prior screen ; drink drink less 14 unit alcohol within six month prior screen ( 1 unit alcohol = 360 mL beer 45 mL spirit 40 % alcohol content 150 mL wine ) 1 . Any history clinically serious disease hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , oncologic , allergic diseases 2 . Clinically significant abnormality laboratory test result 3 . Previous exposure monoclonal antibody current use biologics 4 . History allergic anaphylactic reaction include occur clinical study cause drug excipients 5 . Use prescription non prescription drug dietary supplement , within 5 halflives drug supplement , within 2 week prior take IP ( whichever longer ) . Herbal supplement must discontinue 28 day prior IP 6 . History blood donation within 3 month prior administration IP 7 . Have participate clinical study within 3 month prior administration IP 8 . Have positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody , human immunodeficiency virus ( HIV ) antibodies 9 . Have history drug abuse 10 . Unlikely comply protocol requirement , instruction , study related restriction ; e.g. , uncooperative attitude , inability return followup visit improbability complete whole clinical study , etc .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>